Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT.
Gelfand
Eli V
EV
Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Mass, USA.
Cannon
Christopher P
CP
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology; D002318:Cardiovascular Diseases / Q000517:prevention & control; D023521:Chlamydophila Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016993:Chlamydophila pneumoniae / Q000254:growth & development; D003327:Coronary Disease / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007239:Infections / Q000150:complications; D009203:Myocardial Infarction / Q000188:drug therapy
D000900:Anti-Bacterial Agents